Dr. Lal PathLabs Limited announces the addition of Illumina’s NovaSeq X Series to enhance genomic testing capabilities, ...

The NovaSeq X system, featuring Illumina’s XLEAP-SBS chemistry, can generate more than 20,000 whole genomes per year, more ...

Dr. Lal PathLabs Limited (DLPL), one of India’s most trusted names in diagnostics, has taken a significant leap in the field ...

Diagnostic stocks like Metropolis Healthcare and Dr Lal PathLabs fell up to 3% on June 23 as Amazon launched home diagnostic ...

Nuvama recommends buying HUL, Dr Lal Pathlabs, and IndiaMart for up to 52% potential upside; explore their analysis for ...

Amazon India on Sunday announced the launch of Amazon Diagnostics, an at-home service for customers to book lab tests, ...

The Delhi State Consumer Disputes Redressal Commission reaffirmed that Dr Lal Pathlabs was deficient in service, ordering ...

Dr. Lal Pathlabs Ltd has moved from a long-term downtrend towards a potential uptrend using Wyckoff structure analysis, according to SEBI-registered analyst Harshit Goel. According to Goel, the ...

Holding that the patient's medical expenses were directly attributable to the lab's erroneous report, which falsely indicated ...

Dr. Lal Pathlabs, operating in the Hospitals & Medical Services sector and classified as a Midcap on the BSE, currently has its share price at ₹2904.35. The stock has experienced fluctuations ...

The Delhi State Consumer Disputes Redressal Commission has upheld a ruling against Dr Lal Pathlabs for negligence in ...

Dr Lal Pathlabs (DLPL) has expanded its genomics capabilities by adding Illumina's NovaSeq X Series to its dedicated genomics division, Genevolve. With the integration of Illumina's latest technology, ...